NOV 04, 2019 11:44 AM PST

Gene Variant Could Be a Therapeutic Target For Alzheimer Disease

WRITTEN BY: Nouran Amin

A variation in genetics for an individual at high-risk for Alzheimer development has defied the odds for being dementia-free way beyond anticipated. The individual was a woman who carried a gene mutation prone to the development of early-onset Alzheimer but has not developed the symptoms until 30 years after the expected age of onset. Such observation led researchers on a study funded by the National Institute on Aging (NIA) that highly suggests how a gene variant could be the key to new target therapeutic.

Learn more about Alzheimer disease:

"Sometimes close analysis of a single case can lead to discovery that could have broad implications for the field," said NIA Director Richard J. Hodes, M.D. "We are encouraged that as part of our wide array of studies, this research in the unique genetic makeup of an exceptional individual can reveal helpful information."

In the study, researchers believe that the the woman who carried the gene mutation may have been protected from early Alzheimer symptoms because she also carried two copies of the APOE3 Christchurch (APOE3ch) gene variant. The variant was named after Christchurch, New Zealand were it was first identified.

Early-onset Alzheimer disease is heavily influenced by genetic factors and affects less than 10% of all people who have Alzheimer. The symptoms on average appear between 30 to 60 years of age. Experiments demonstrated in the study sought to address how the APOE3ch variant may reduce the brains ability from forming plaques—a hallmark of the disease.

Findings were published in the paper, “Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report” and shows how APOE3ch variant holds the potential to be a new way of treating or preventing Alzheimer disease.

Source: National Institute on Aging

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 15, 2020
Drug Discovery & Development
New Antibiotic 'Irresistin' Defeats All Resistant Bacteria
JUN 15, 2020
New Antibiotic 'Irresistin' Defeats All Resistant Bacteria
Researchers from Princeton University have identified a compound capable of killing both Gram-positive and Gram-negative ...
JUN 26, 2020
Cancer
Combining Treatments to Improve Acute Myeloid Leukemia Therapy
JUN 26, 2020
Combining Treatments to Improve Acute Myeloid Leukemia Therapy
Acute myeloid leukemia (AML) is a type of blood cancer that prevents the complete maturation of stem cells. These immatu ...
JUL 01, 2020
Cancer
The MicroRNA That Can Regulate Tumor Vascularization in Liver Cancer
JUL 01, 2020
The MicroRNA That Can Regulate Tumor Vascularization in Liver Cancer
Angiogenesis is the vascularization, or generation of blood vessels, of a part of the body. It is a normal function of h ...
JUL 13, 2020
Drug Discovery & Development
Russia Completes First Human Trial for COVID-19 Vaccine
JUL 13, 2020
Russia Completes First Human Trial for COVID-19 Vaccine
The Sechenov University Center for Clinical Research in Moscow, Russia, has completed its first round of clinical trials ...
JUL 17, 2020
Drug Discovery & Development
Could Low-Dose Radiation Therapy Treat COVID-19?
JUL 17, 2020
Could Low-Dose Radiation Therapy Treat COVID-19?
Research from a century ago points towards the potential of low-dose radiation therapy (LDRT) for treating pneumonia. Ev ...
JUL 19, 2020
Drug Discovery & Development
Synapse-Saving Proteins Could Stave Off Alzheimer's
JUL 19, 2020
Synapse-Saving Proteins Could Stave Off Alzheimer's
Researchers at the University of Texas have identified a new subset of proteins capable of protecting synapses- the stru ...
Loading Comments...